110 related articles for article (PubMed ID: 12269768)
1. Intermittent, repetitive administrations of irinotecan (CPT-11) reduces its side-effects.
Fujii H; Koshiyama M; Konishi M; Yoshida M; Tauchi K
Cancer Detect Prev; 2002; 26(3):210-2. PubMed ID: 12269768
[TBL] [Abstract][Full Text] [Related]
2. Retrospective comparative study of irinotecan and pegylated liposomal doxorubicin for platinum-resistant or -refractory epithelial ovarian and primary peritoneal carcinoma.
Ichikawa R; Torii Y; Oe S; Kawamura K; Kato R; Hasegawa K; Udagawa Y
Arch Gynecol Obstet; 2014 Nov; 290(5):979-84. PubMed ID: 24798935
[TBL] [Abstract][Full Text] [Related]
3. Salvage chemotherapy with CPT-11 for recurrent meningioma.
Chamberlain MC; Tsao-Wei DD; Groshen S
J Neurooncol; 2006 Jul; 78(3):271-6. PubMed ID: 16628476
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of irinotecan (CPT-11) in patients with advanced squamous cell carcinoma of the cervix.
Irvin WP; Price FV; Bailey H; Gelder M; Rosenbluth R; Durivage HJ; Potkul RK
Cancer; 1998 Jan; 82(2):328-33. PubMed ID: 9445190
[TBL] [Abstract][Full Text] [Related]
5. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
[TBL] [Abstract][Full Text] [Related]
6. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma.
Rothenberg ML; Cox JV; DeVore RF; Hainsworth JD; Pazdur R; Rivkin SE; Macdonald JS; Geyer CE; Sandbach J; Wolf DL; Mohrland JS; Elfring GL; Miller LL; Von Hoff DD
Cancer; 1999 Feb; 85(4):786-95. PubMed ID: 10091755
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.
Rowinsky EK; Grochow LB; Ettinger DS; Sartorius SE; Lubejko BG; Chen TL; Rock MK; Donehower RC
Cancer Res; 1994 Jan; 54(2):427-36. PubMed ID: 8275479
[TBL] [Abstract][Full Text] [Related]
8. Low-dose irinotecan as a second-line chemotherapy for recurrent small cell lung cancer.
Morise M; Niho S; Umemura S; Matsumoto S; Yoh K; Goto K; Ohmatsu H; Ohe Y
Jpn J Clin Oncol; 2014 Sep; 44(9):846-51. PubMed ID: 25057092
[TBL] [Abstract][Full Text] [Related]
9. A dose-escalation study of irinotecan (CPT-11) in combination with cisplatin in patients with advanced non-small cell lung cancer previously treated with a docetaxel-based front line chemotherapy.
Kakolyris S; Souglakos J; Agelaki S; Kourousis CH; Mavroudis D; Sarra E; Malliotakis P; Georgoulias V
Lung Cancer; 2000 Dec; 30(3):193-8. PubMed ID: 11137204
[TBL] [Abstract][Full Text] [Related]
10. [A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Research Groups of CPT-11 in Gynecologic Cancers].
Takeuchi S; Dobashi K; Fujimoto S; Tanaka K; Suzuki M; Terashima Y; Hasumi K; Akiya K; Negishi Y; Tamaya T
Gan To Kagaku Ryoho; 1991 Aug; 18(10):1681-9. PubMed ID: 1872624
[TBL] [Abstract][Full Text] [Related]
11. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer.
Masuda N; Fukuoka M; Kudoh S; Matsui K; Kusunoki Y; Takada M; Nakagawa K; Hirashima T; Tsukada H; Yana T
J Clin Oncol; 1994 Sep; 12(9):1833-41. PubMed ID: 7521905
[TBL] [Abstract][Full Text] [Related]
12. Irinotecan hydrochloride for the treatment of recurrent and refractory non-Hodgkin lymphoma: a single institution experience.
Sugiyama K; Omachi K; Fujiwara K; Saotome T; Mizunuma N; Takahashi S; Ito Y; Aiba K; Horikoshi N
Cancer; 2002 Feb; 94(3):594-600. PubMed ID: 11857289
[TBL] [Abstract][Full Text] [Related]
13. Relationship between the pharmacokinetics of irinotecan and diarrhea during combination chemotherapy with cisplatin.
Kudoh S; Fukuoka M; Masuda N; Yoshikawa A; Kusunoki Y; Matsui K; Negoro S; Takifuji N; Nakagawa K; Hirashima T
Jpn J Cancer Res; 1995 Apr; 86(4):406-13. PubMed ID: 7775263
[TBL] [Abstract][Full Text] [Related]
14. [Combination of irinotecan hydrochloride (CPT-11) and cisplatin as a new regimen for patients with advanced ovarian cancer].
Sugiyama T; Nishida T; Kataoka A; Imaishi K; Komai K; Ushijima K; Hasuo Y; Ookura N; Yakushiji M
Nihon Sanka Fujinka Gakkai Zasshi; 1996 Sep; 48(9):827-34. PubMed ID: 8841050
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of irinotecan (CPT-11) as salvage therapy for advanced nasopharyngeal carcinoma.
Poon D; Chowbay B; Cheung YB; Leong SS; Tan EH
Cancer; 2005 Feb; 103(3):576-81. PubMed ID: 15612023
[TBL] [Abstract][Full Text] [Related]
16. [Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group].
Futatsuki K; Wakui A; Nakao I; Sakata Y; Kambe M; Shimada Y; Yoshino M; Taguchi T; Ogawa N
Gan To Kagaku Ryoho; 1994 Jun; 21(7):1033-8. PubMed ID: 8210254
[TBL] [Abstract][Full Text] [Related]
17. Irinotecan and mitomycin C in 5-fluorouracil-refractory colorectal cancer patients. A phase I/II study of the Southern Italy Cooperative Oncology Group.
Comella P; Biglietto M; Casaretti R; De Lucia L; Avallone A; Maiorino L; Di Lullo L; De Cataldis G; Rivellini F; Comella G
Oncology; 2001; 60(2):127-33. PubMed ID: 11244327
[TBL] [Abstract][Full Text] [Related]
18. [An early phase II study of CPT-11 (irinotecan hydrochloride) in patients with advanced breast cancer].
Taguchi T; Yoshida Y; Izuo M; Ishida T; Ogawa M; Nakao I; Tominaga T; Ohkawa T; Oguro M; Yoshida M
Gan To Kagaku Ryoho; 1994 Jan; 21(1):83-90. PubMed ID: 8291919
[TBL] [Abstract][Full Text] [Related]
19. A phase II trial of irinotecan in patients with advanced or recurrent endometrial cancer and correlation with biomarker analysis.
Nishio S; Shimokawa M; Tasaki K; Nasu H; Yoshimitsu T; Matsukuma K; Terada A; Tsuda N; Kawano K; Ushijima K
Gynecol Oncol; 2018 Sep; 150(3):432-437. PubMed ID: 30037491
[TBL] [Abstract][Full Text] [Related]
20. [Usefulness of clinical study of irinotecan and cisplatin for recurrent ovarian cancer].
Yahagi N; Kobayashi Y; Ohara T; Kondo H; Suzuki N; Kiguchi K; Ishizuka B
Gan To Kagaku Ryoho; 2009 Dec; 36(13):2583-6. PubMed ID: 20009459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
